Apixaban for late portal vein clot after spleen surgery
Treatments studied
Part of Blood & lymphatic, Digestive system clinical trials.
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (scarring of the liver).
- You had bleeding from enlarged veins in your esophagus or stomach due to liver disease.
- You had your spleen removed by laparoscopic surgery at our center.
- Your spleen surgery was more than a year ago, and you developed a blood clot in the main vein to your liver after that.
- You do not have active cancer, a bleeding disorder, or use certain blood-thinning medications.
- You are not pregnant and do not have uncontrolled high blood pressure or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This trial looks at whether a minimally invasive spleen surgery (with a specific vein-disconnection procedure) can better protect liver function in people with cirrhosis who have had variceal bleeding. It may help reduce stress on the liver after treatment, but you must meet several safety criteria.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.